Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01_AE env gene derived from HIV-1-infected patient, residing in central Thailand

Microbes and Infection

Volumn 11, Issue 3, 2009, Pages 334-343

  Utachee, Piraporn ^a   Jinnopat, Piyamat ^a   Isarangkura na ayuthaya, Panasda ^b   de Silva, U Chandimal ^a,c   Nakamura, Shota ^a,c   Siripanyaphinyo, Uamporn ^a,c   Wichukchinda, Nuanjun ^b   Tokunaga, Kenzo ^d   Yasunaga, Teruo ^a,c   Sawanpanyalert, Pathom ^b   Ikuta, Kazuyoshi ^a,c   Auwanit, Wattana ^b   Kameoka, Masanori ^a,c  

^a Thailand Japan Research Collaboration Center on Emerging and Re emerging Infections RCC ERI   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

^c OSAKA UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

HIV entry inhibitors; HIV envelope glycoprotein gp120; HIV envelope glycoprotein gp41; HIV 1; Neutralization tests

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY B12; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ARTICLE; ENVELOPE GENE; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PHENOTYPE; PLASMA; PRIORITY JOURNAL; THAILAND; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT;

ANTIBODIES, MONOCLONAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; RECEPTORS, HIV; RECOMBINATION, GENETIC; THAILAND;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 62949178780     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2008.12.008     Document Type: Article

References (29)

1. Gaschen B., Taylor J., Yusim K., Foley B., Gao F., Lang D., Novitsky V., Haynes B., Hahn B.H., Bhattacharya T., and Korber B. Diversity considerations in HIV-1 vaccine selection. Science 296 (2002) 2354-2360
2. Hemelaar J., Gouws E., Ghys P.D., and Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20 (2006) W13-W23
3. Levy J.A. Steps involved in HIV: cell interaction and virus entry. HIV and the Pathogenesis of AIDS. third ed. (2007), ASM Press, Washington, DC 55-78
4. Haynes B.F., and Montefiori D.C. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccines 5 (2006) 579-595
5. Brown B.K., Darden J.M., Tovanabutra S., Oblander T., Frost J., Sanders-Buell E., de Souza M.S., Birx D.L., McCutchan F.E., and Polonis V.R. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J. Virol. 79 (2005) 6089-6101
6. Chuenchitra T., Wasi C., Louisirirojchanakul S., Nitayaphan S., Sutthent R., Cox J.H., de Souza M.S., Brown A.E., Birx D.L., and Polonis V.R. Longitudinal study of humoral immune responses in HIV type 1 subtype CRF01_AE (E)-infected Thai patients with different rate of disease progression. AIDS Res. Hum. Retroviruses 19 (2003) 293-305
7. Kato K., Sato H., and Takebe Y. Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism. J. Virol. 73 (1999) 5520-5526
8. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Ollmann Saphire E., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., and Parren P.W.H.I. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75 (2001) 10892-10905
9. P. Utachee, P. Jinnopat, P. Isarangkura-na-ayuthaya, U.C. de Silva, S. Nakamura, U. Siripanyaphinyo, N. Wichukchinda, K. Tokunaga, T. Yasunaga, P. Sawanpanyalert, K. Ikuta, W. Auwanit, M. Kameoka, Genotypic characterization of CRF01_AE env genes derived from human immunodeficiency virus type 1-infected patients residing in central Thailand, AIDS Res. Hum. Retroviruses 25 (2009) 229-236.
10. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., and Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59 (1986) 284-291
11. Kinomoto M., Yokoyama M., Sato H., Kojima A., Kurata T., Ikuta K., Sata T., and Tokunaga K. Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implication for the molecular mechanism of viral escape from a fusion inhibitor. J. Virol. 79 (2005) 5996-6004
12. Kitagawa Y., Kameoka M., Shoji-Kawata S., Iwabu Y., Mizuta H., Tokunaga K., Fujino M., Natori Y., Yura Y., and Ikuta K. Inhibitory function of adaptor-related protein complex 2 alpha 1 subunit in the process of nuclear translocation of human immunodeficiency virus type 1 genome. Virology 373 (2008) 171-180
13. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., and Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70 (1996) 1100-1108
14. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W.H.I., Sawyer L.S.W., Hendry R.M., Dunlop N., Nara P.L., Lamacchia M., Garratty E., Steihm E.R., Bryson Y.J., Cao Y., Moore J.P., Ho D.D., and Barbas III C.F. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266 (1994) 1024-1027
15. Purtscher M., Trkola A., Gruber G., Buchacher A., Predl R., Steindl F., Tauer C., Berger R., Barrett B., Jungbauer A., and Katinger H. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 10 (1994) 1651-1658
16. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., and Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 17 (2001) 1757-1765
17. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Aramaki Y., Okonogi K., Ogawa Y., Meguro K., and Fujino M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 5698-5703
18. Wild C.T., Shugars D.C., Greenwell T.K., McDanal C.B., and Matthews T.J. Peptide corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 9770-9774
19. Björndal A., Deng H., Jansson M., Fiore J.R., Colognesi C., Karlsson A., Albert J., Scarlatti G., Littman D.R., and Fenyö E.M. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71 (1997) 7478-7487
20. Barbas III C.F., Collet T.A., Amberg W., Roben P., Binley J.M., Hoekstra D., Cababa D., Jones T.M., Williamson R.A., Pilkington G.R., Haigwood N.L., Cabezas E., Satterthwait A.C., Sanz I., and Burton D.R. Molecular profile of an antibody responses to HIV-1 as probed by combinatorial libraries. J. Mol. Biol. 230 (1993) 812-823
21. Sanders R.W., Venturi M., Schiffner L., Kalyanaraman R., Katinger H., Lloyd K.O., Kwong P.D., and Moore J.P. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76 (2002) 7293-7305
22. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Rüker F., and Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67 (1993) 6642-6647
23. Briz V., Poveda E., and Soriano V. HIV entry inhibitors: mechanisms of action and resistance pathways. J. Antimicrob. Chemother. 57 (2006) 619-627
24. Li M., Salazar-Gonzalez J.F., Derdeyn C.A., Morris L., Williamson C., Robinson J.E., Decker J.M., Li Y., Salazar M.G., Polonis V.R., Mlisana K., Karim S.A., Hong K., Greene K.M., Bilska M., Zhou J., Allen S., Chomba E., Mulenga J., Vwalika C., Gao F., Zhang M., Korber B.T.M., Hunter E., Hahn B.H., and Montefiori D.C. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in southern Africa. J. Virol. 80 (2006) 11776-11790
25. Mo H., Stamatatos L., Ip J.E., Barbas C.F., Parren P.W.H.I., Burton D.R., Moore J.P., and Ho D.D. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. J. Virol. 71 (1997) 6869-6874
26. Mascola J.R., and Montefiori D.C. HIV-1: nature's master of disguise. Nat. Med. 9 (2003) 393-394
27. Quakkelaar E.D., van Alphen F.P.J., Boeser-Nunnink B.D.M., van Nuenen A.C., Pantophlet R., and Schuitemaker H. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies. J. Virol. 81 (2007) 8533-8542
28. Pinter A., Honnen W.J., He Y., Gorny M.K., Zolla-Pazner S., and Kayman S.C. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J. Virol. 78 (2004) 5205-5215
29. Rong R., Bibollet-Ruche F., Mulenga J., Allen S., Blackwell J.L., and Derdeyn C.A. Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J. Virol. 81 (2007) 1350-1359